Premium
Time course and clinical characterization of cisplatin‐induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population
Author(s) -
Chan Sze Ling,
Ng Li Shia,
Goh Xueying,
Siow Chor Hiang,
Goh Han Lee,
Goh Boon Cher,
Cheo Timothy,
Loh Kwok Seng,
Brunham Liam R.
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25112
Subject(s) - common terminology criteria for adverse events , medicine , nasopharyngeal carcinoma , ototoxicity , chemoradiotherapy , radiation therapy , hearing loss , adverse effect , cisplatin , oncology , audiology , chemotherapy
Background The purpose of this study was to characterize the clinical course of hearing loss in patients with nasopharyngeal carcinoma (NPC) and the clinical factors affecting its severity. Methods The time course of hearing loss in patients with NPC was assessed using threshold shift from baseline and Common Terminology Criteria for Adverse Events (CTCAE) grade. Results In the chemoradiotherapy (CRT) groups, the threshold shift was significantly higher from 3 months at 4 kHz ( P = 2.30 × 10 −9 , concurrent CRT only) but not within 2 years posttreatment in the radiotherapy (RT) group. The CRT groups had worse CTCAE grades than the RT group (percentage of latest CTCAE grade ≥1: 64.9% vs 29.0%, respectively). Cumulative cisplatin dose and cochlear RT dose significantly affects threshold shifts, especially at high frequencies. Conclusion Although cisplatin led to high frequency hearing impairment from about 3 months posttreatment, RT conferred no significant hearing impairment in the first 2 years.